Leverkusen

Pan American Announces Marketing Program

Retrieved on: 
Saturday, November 11, 2023

CALGARY, Alberta, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (the “Company” or “Pan American”) (CSE: PNRG) (OTC PINK: PAANF) (FRA: SS60) is pleased to announce that it has engaged MIC Market Information & Content Publishing GmbH (“MIC”) (address: Gerhart-Hauptmann-Str.

Key Points: 
  • CALGARY, Alberta, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (the “Company” or “Pan American”) (CSE: PNRG) (OTC PINK: PAANF) (FRA: SS60) is pleased to announce that it has engaged MIC Market Information & Content Publishing GmbH (“MIC”) (address: Gerhart-Hauptmann-Str.
  • 49b, 51379 Leverkusen; email: [email protected]) for marketing services for an anticipated period of two months commencing on November 13, 2023, provided that the term of the marketing services may be extended or shortened at the discretion of management depending on, amongst other things, the efficiency of the marketing services.
  • The marketing services will include project management and consulting to develop online marketing campaigns, coordinating marketing actions, maintaining and optimizing AdWords campaigns, adapting AdWords bidding strategies, optimizing AdWords ads and creating and optimizing landing pages.
  • The Company will not issue any securities to MIC as compensation for its marketing services.

MANTARO PRECIOUS METALS CORP. PROVIDES CORPORATE UPDATE

Retrieved on: 
Wednesday, April 19, 2023

Tailings Study: The Company is currently exploring the option of re-processing the tailings on site or selling them to a third party.

Key Points: 
  • Tailings Study: The Company is currently exploring the option of re-processing the tailings on site or selling them to a third party.
  • Previously, the Company took sixteen samples each of 5 kg for metallurgical test-work (See news release dated December 2, 2021).
  • Drill Pad Construction: Following cessation of the wet season, the Company anticipates that it re-commence drill pad construction in May of 2023.
  • Golden Hill was mined historically for gold from alluvial drainages along a 6 km long trend within the concession.

AWS and DFL Unveil Two New Bundesliga Match Facts for the 2022–23 German Football Season

Retrieved on: 
Friday, September 30, 2022

Fans can learn more about how AWS is transforming the sports industry with the Bundesliga on the AWS Bundesliga site .

Key Points: 
  • Fans can learn more about how AWS is transforming the sports industry with the Bundesliga on the AWS Bundesliga site .
  • These new stats bring the total of Bundesliga Match Facts powered by AWS to 12, delivering a comprehensive set of real-time advanced analysis to millions of Bundesliga fans around the world.
  • The DFL Deutsche Fuball Liga generates Bundesliga Match Facts by gathering and analyzing a total of 3.6 million data points from each game in real time.
  • The two new Match Facts this season will provide even greater detail and analysis, and, together with AWS, Im thrilled to see how our Match Facts evolve.

Biofrontera AG announces mediation results

Retrieved on: 
Friday, November 19, 2021

Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group").

Key Points: 
  • Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group").
  • At the upcoming Annual General Meeting of Biofrontera AG on December 14, 2021, new elections to the Supervisory Board will be held as scheduled.
  • In the course of the mediation process, agreement was reached between the Deutsche Balaton Group and the incumbent Supervisory Board of Biofrontera AG on the candidates for the Supervisory Board.
  • The settlement is subject to the condition precedent that the aforementioned candidates are elected to the Supervisory Board of Biofrontera AG by December 31, 2021 at the latest.

Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

Retrieved on: 
Wednesday, November 17, 2021

A comparison with product sales in 2019 shows that overall product sales since the beginning of 2021 have been back at pre-pandemic levels.

Key Points: 
  • A comparison with product sales in 2019 shows that overall product sales since the beginning of 2021 have been back at pre-pandemic levels.
  • This is despite the fact that the first few months were still heavily impacted by the pandemic, particularly in the United States.
  • Unchanged from the ownership structure of Biofrontera Inc., Biofrontera AG will thereby benefit directly from growing Ameluz sales in the USA.
  • The Management Board therefore maintains its guidance for the fiscal year 2021 published on April 12, 2021 in its entirety.

Biofrontera AG announces initiation of clinical studies

Retrieved on: 
Tuesday, November 16, 2021

Both studies are focused on optimizing market positioning and expanding market share for our FDA-approved prescription drug Ameluz for photodynamic therapy in our largest market, the United States, says Hermann Lbbert, CEO of Biofrontera AG.

Key Points: 
  • Both studies are focused on optimizing market positioning and expanding market share for our FDA-approved prescription drug Ameluz for photodynamic therapy in our largest market, the United States, says Hermann Lbbert, CEO of Biofrontera AG.
  • Site initiations for both studies are underway with patient recruitment to start before the end of the year.
  • This study comes on the back of a maximal-usage pharmacokinetics (PK) clinical study completed in early 2021.
  • Ameluz together with the PDT-lamp BF-RhodoLED and its successor model BF-RhodoLED XL is being marketed by Biofrontera Inc, a US-based affiliate of Biofrontera AG under an exclusive license and supply agreement for the United States.

Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021

Retrieved on: 
Tuesday, November 9, 2021

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

Key Points: 
  • Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.
  • The Germany-based company develops and markets innovative products for the care, protection and treatment of the skin.
  • In the EU, the company also sells the dermocosmetics series Belixos, which offers specialized care for damaged or diseased skin.
  • Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house.

Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp

Retrieved on: 
Friday, October 22, 2021

In accordance with FDA requirements, the approval was granted as a combination approval with our prescription drug Ameluz, same as the approval with the predecessor model BF-RhodoLED.

Key Points: 
  • In accordance with FDA requirements, the approval was granted as a combination approval with our prescription drug Ameluz, same as the approval with the predecessor model BF-RhodoLED.
  • The new PDT lamp enables the illumination of larger areas, enabling the simultaneous treatment of several actinic keratoses distant from each other.
  • The treatment parameters of the new BF-RhodoLED XL, such as light dose, illumination time and wavelength of light are identical to the predecessor model BF-RhodoLED.
  • At present, there are no plans to market the new BF-RhodoLED XL in Europe.

Biofrontera reports preliminary approximate revenues for the month of September 2021

Retrieved on: 
Friday, October 1, 2021

The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin.

Key Points: 
  • The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin.
  • Ameluz has been marketed in the EU since 2012 and in the United States since May 2016.
  • In the EU, the company also sells the dermocosmetics series Belixos, which offers specialized care for damaged or diseased skin.
  • Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house.

Biofrontera reports preliminary revenue for the month of August 2021

Retrieved on: 
Wednesday, September 8, 2021

The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin.

Key Points: 
  • The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin.
  • Ameluz has been marketed in the EU since 2012 and in the United States since May 2016.
  • In the EU, the company also sells the dermocosmetics series Belixos, which offers specialized care for damaged or diseased skin.
  • Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house.